RecruitingPhase 1NCT07419841

A Phase 1 Study of the Safety and Tolerability of CTX-10726

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients With Advanced Malignancies

Sponsor

Compass Therapeutics

Enrollment

70 participants

Start Date

May 28, 2026

Study Type

INTERVENTIONAL

Conditions

Endometrial Cancer Renal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)Gastroesophageal Cancer (GC)

Summary

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CTX-10726 for people with endometrial cancer, gastroesophageal cancer (gc), and other related conditions. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.